Patient Disease Trajectories in Rheumatoid Arthritis Patients Treated with Baricitinib 4-mg in Four Phase 3 Clinical Studies

Plain Language Summary Baricitinib is an oral agent widely approved for the treatment of moderately to severely active rheumatoid arthritis). Although baricitinib (and other agents) have demonstrated efficacy at the population level, treatment responses vary considerably between individual patients....

ver descrição completa

Detalhes bibliográficos

Principais autores:	Peter C. Taylor, Yun-Fei Chen, Janet Pope, Michael Weinblatt, Eduardo Mysler, Andrea Rubbert-Roth, Bochao Jia, Luna Sun, Yushi Liu, Thorsten Holzkämper, Yoshiya Tanaka
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Adis, Springer Healthcare 2023-01-01
coleção:	Rheumatology and Therapy
Assuntos:	Baricitinib Growth mixture modeling Rheumatoid arthritis Trajectory
Acesso em linha:	https://doi.org/10.1007/s40744-022-00529-7
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!